Using oncology care pathways and treatment pathways has helped practices use evidence-based data to facilitate them to be sure they are using the right drug for the right patient at the right time, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.
Using oncology care pathways and treatment pathways has helped practices use evidence-based data to facilitate them to be sure they are using the right drug for the right patient at the right time, said Ray Page, DO, PhD, president and director of research at The Center for Cancer and Blood Disorders.
Transcript
How are physicians using data at the point-of-care today?
We’re trying to increasingly use that kind of data at the point of care to help make behavior modifications for our physicians to help us identify some of these risk stratifiers that are occurring. Certainly 1 thing that our practice has done for many years is just the utilization of oncology care pathways and treatment pathways, and just being able to use that kind of evidence-based data to facilitate us in assuring that we’re using the right drug for the right patient at the right time, it goes a long way just utilizing treatments pathways.
I’ll emphasize also that as we find these quality measures and these benchmarks and these standards and these interventions that this is very much a team approach and as we take care of our cancer patients and get them through the journey with their cancer, we do have an entire team that manages those. There’s certain data elements that occur at the physician level that we manage but then there’s other data elements that will go to our advanced practitioners to manage.
Then there’s other data elements and processes that occur that go to our case managers and our triage nurses and our chemotherapy nurses and then all of our ancillary services that we have so that we can actually utilize everybody in the team to function at their highest level to assure that our patients are getting all the touches and the contacts that they need in order to have optimal outcomes.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More